<DOC>
	<DOC>NCT00848484</DOC>
	<brief_summary>This study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.</brief_summary>
	<brief_title>Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Patient is male between 21 and 55 years of age Duration of the illness must be longer than 1 year Patient's current antipsychotic medication regimen must be stable Patient is negative for selected drugs of abuse at Screening Must be in a stable living arrangement for at least 3 months prior to screening (not a homeless shelter) Patient has mental retardation Undergone Electroconvulsive Therapy (ECT) treatment within 6 months prior to screening Has suicidal attempts or ideation within the last 12 months Patient has a history of alcohol/drug dependence within 1 year or alcohol/drug abuse within 12 months of starting the study</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>